The concern of generic challenges has repeatedly loomed over copyright’s blockbuster drug, Viagra, sparking questions about the outlook of related medicinal stakes. While first periods saw impressive profits, the exclusivity expiration has allowed the door for less expensive alternatives, likely lowering revenue and presenting a genuine risk for